16 June 2025 : Clinical Research
Effects of Weight Loss on Insulin Resistance and Liver Health in T2DM and NAFLD Patients
Xu Yang ACDF 1*, Qifang Meng BDEG 1, Pingyu Wu BCF 1DOI: 10.12659/MSM.947157
Med Sci Monit 2025; 31:e947157
Table 1 Baseline characteristics of compliant (Group B) and non-compliant (Group A) patients.
| Group A (n=11) | Group B (n=26) | P | |
|---|---|---|---|
| Men/women (n) | 8/3 | 23/3 | – |
| Age (y.) | 39.27±9.64 | 34.85±9.18 | 0.158 |
| BMI (kg/m) | 29.36±4.39 | 29.38±4.25 | 0.921 |
| Weight (kg) | 86.45±16.60 | 88.81±17.54 | 0.714 |
| height (cm) | 171.09±5.85 | 173.31±7.25 | 0.342 |
| TBIL (μmol/L) | 14.95±7.97 | 16.82±9.90 | 0.842 |
| TG (mmol/L) | 4.32±2.30 | 4.49±3.58 | 0.595 |
| TC (mmol/L) | 5.36±1.09 | 4.89±1.21 | 0.219 |
| LDL-c (mmol/L) | 3.49±1.16 | 3.08±0.84 | 0.528 |
| HDL-c (mmol/L) | 1.04±0.19 | 0.99±0.23 | 0.465 |
| ALP (U/L) | 94.27±21.57 | 89.77±28.73 | 0.378 |
| LDH (U/L) | 202.09±71.45 | 207.67±44.78 | 0.319 |
| ALT (U/L) | 98.27±71.13 | 115.42±63.28 | 0.416 |
| AST (U/L) | 46.64±25.29 | 57.73±31.57 | 0.238 |
| GGT.γ (U/L) | 120.64±66.98 | 108.77±88.51 | 0.572 |
| FBG | 7.17±2.18 | 7.25±2.23 | 0.947 |
| HOMA-IR | 5.35±3.97 | 5.67±3.65 | 0.740 |
| (MRI) Liver fat content | 16.45±9.22 | 14.92±6.21 | 0.947 |
| Values are expressed as mean±SD. ≤0.05, Mann-Whitney test. BMI – body-mass index; HOMA-IR – homeostatic model assessment for insulin resistance; TBIL – total bilirubin; TG – triglycerides; TC – total cholesterol; LDL-c – low-density lipoprotein; HDL-c – high-density lipoprotein; ALP – alkaline phosphatase; LDH – lactate dehydrogenase; ALT – alanine aminotransferase; AST – aspartate aminotransferase; GGT – gamma-glutamyl transferase; FBG – fasting blood glucose. values are from mixed-effects analysis. | |||